Is This the End of Dry Eye? New Dry Eyes Treatments Revealed!

Dr. Joseph Allen, an optometrist from Minnesota, introduces the topic of new dry eye treatments. He discusses the symptoms of dry eye disease, such as redness, irritation, and a foreign body sensation, and mentions an upcoming release of new treatments. Dr. Allen also expresses gratitude to his channel members for their support and for choosing the topic of the live stream. He invites viewers to share their experiences with dry eye symptoms and any treatments that have helped them, setting the stage for an educational discussion on over-the-counter options, medications, and in-office procedures.

The discussion begins with over-the-counter options for managing dry eyes. Dr. Allen mentions a product called 'drye drink,' which contains anti-inflammatory ingredients, electrolytes, and vitamins supportive of ocular health. He shares his experience with the PM version of the drink, which includes sleep aids like passionflower and valerian root, and discusses the importance of sleep quality in relation to dry eye symptoms. He also talks about makeup lines designed for sensitive eyes and a new product from Bosan LOM, which is available in eye care aisles and has undergone clinical trials for safety and efficacy.

Dr. Allen shifts the focus to in-office procedures, starting with Rinada, a device that flushes debris from under the eyelids, potentially reducing inflammation associated with dry eye. He references a study showing a reduction in Matrix metalloproteinase 9, an inflammatory marker, after using the Rinada device. Another procedure discussed is Tear Care, a warming device that melts oil glands in the eyelids and is compared to Restasis, a long-standing treatment for dry eye. The study suggests Tear Care may be as effective, if not superior, and could be more affordable due to Restasis being generic and often covered by insurance.

The conversation moves to prescription treatments, beginning with Xdy, a medication for Demodex blepharitis, which is linked to dry eye. Dr. Allen explains the role of Demodex mites in eyelid inflammation and the benefits of Xdy in reducing these symptoms. He also covers a new medication called Meibo, which is a substitute for the oil layer of the tear film, helping to prevent tear evaporation and lubricate the eyelids. Clinical trials have shown improvements in corneal staining and dry eye symptom scores with the use of Meibo.

Dr. Allen explores future medications and treatments under investigation, such as a cream by Azura Ophthalmic containing selenium sulfide to treat keratin buildup in meibomian gland dysfunction. He also discusses Cloudbreak Pharma's CBT 00006, an eye drop aimed at dissolving cholesterol and lipids in the eyelids. Additionally, he mentions a higher-strength cyclosporine A with perfluorohexyloctane, which may work faster and more comfortably than existing treatments. Other treatments include a cyclosporin-loaded punctal plug and AR1 15512, a TRPM8 agonist, which has the potential to improve basal tear production and reduce ocular pain.

Dr. Allen highlights Lacroprep by Tear Solutions, a formulation designed to supplement and protect lactin, a protein reduced in dry eye. Animal studies have shown increased tear production with Lacroprep, and phase one and two trials in humans with Sjögren's syndrome have demonstrated improved tear secretion, corneal health, and symptoms. Furthermore, Lacroprep has shown potential in promoting corneal nerve regeneration, which could be a game-changer for treating dry eye and other conditions affecting the eye.

The session concludes with a Q&A segment where Dr. Allen addresses various questions from viewers. He provides insights on the potential of generic versions of Zyra, the cost of Tear Care, and the sensitivity of the eyes. He also discusses the causes of dry eye, the challenges of treating corneal scarring, and the possibility of reversing meibomian gland dysfunction (MGD) caused by treatments like Accutane. Dr. Allen emphasizes the importance of consulting with a local eye care provider for proper diagnosis and treatment and shares his practice location for those interested in his services.

In the final part of the session, Dr. Allen discusses the potential impact of diet on meibomian gland dysfunction (MGD) and dry eye. He suggests that diet may play a significant role, with some evidence linking the microbiome to eye disease and the potential benefits of omega-3 fatty acids for tear film stability. Dr. Allen acknowledges the complexity of the issue and the need for further research, but he also shares anecdotes from viewers who have experienced dry eye improvements through dietary changes. He encourages viewers to explore the connection between diet and eye health further.